Prexton begins Phase II of foliglurax for PD

Prexton Therapeutics S.A. (Geneva, Switzerland) began the double-blind, placebo-controlled, European Phase II AMBLED trial to evaluate 10 and 30 mg doses of oral foliglurax (PXT002331) for 28 days in 165 patients with Parkinson’s disease (PD) treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and levodopa-induced dyskinesia.

The primary endpoint of AMBLED is the change from baseline to day 28 in daily awake "off" time. Data are expected in 2019...